3,109
Views
11
CrossRef citations to date
0
Altmetric
Commentary

Chasing down the triple-negative myeloproliferative neoplasms: Implications for molecular diagnostics

Article: e1248011 | Received 07 Oct 2016, Accepted 10 Oct 2016, Published online: 14 Nov 2016

REFERENCES

  • Nangalia J, Grinfeld J, Green AR. Pathogenesis of myeloproliferative disorders. Annu Rev Pathol 2016; 11:101-26; PMID:27193452; http://dx.doi.org/10.1146/annurev-pathol-012615-044454
  • Langabeer SE, Andrikovics H, Asp J, Bellosillo B, Carillo S, Haslam K, Kjaer L, Lippert E, Mansier O, Oppliger Leibundgut E, et al. Molecular diagnostics of myeloproliferative neoplasms. Eur J Haematol 2015; 95(4):270-9; PMID:25951317; http://dx.doi.org/10.1111/ejh.12578
  • Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127(20):2391-405; PMID:27069254; http://dx.doi.org/10.1182/blood-2016-03-643544
  • Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, Gangat N, Fjerza R, Belachew AA, Lasho TL, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood 2014; 124(16):2507-13; PMID:25037629; http://dx.doi.org/10.1182/blood-2014-05-579136
  • Schnittger S, Bacher U, Kern W, Schröder M, Haferlach T, Schoch C. Report on two novel nucleotide exchanges in the JAK2 pseudokinase domain: D620E and E627E. Leukemia 2006; 20(12):2195-7; PMID:16871281; http://dx.doi.org/10.1038/sj.leu.2404325
  • Cleyrat C, Jelinek J, Girodon F, Boissinot M, Ponge T, Harousseau JL, Issa JP, Hermouet S. JAK2 mutation and disease phenotype: a double L611V/V617F in cis mutation of JAK2 is associated with isolated erythrocytosis and increased activation of AKT and ERK1/2. Leukemia 2010; 24(5):1069-73; PMID:20182460; http://dx.doi.org/10.1038/leu.2010.23
  • Chaligné R, Tonetti C, Besancenot R, Roy L, Marty C, Mossuz P, Kiladjian JJ, Socié G, Bordessoule D, Le Bousse-Kerdilès MC, et al. New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition. Leukemia 2008; 22(8):1557-66; http://dx.doi.org/10.1038/leu.2008.137
  • Schnittger S, Bacher U, Haferlach C, Beelen D, Bojko P, Bürkle D, Dengler R, Distelrath A, Eckart M, Eckert R, et al. Characterization of 35 new cases with four different MPL W515 mutations and essential thrombocythemia or primary myelofibrosis. Haematologica 2009; 94(1):141-4; PMID:19029146; http://dx.doi.org/10.3324/haematol.13224
  • Gong JZ, Cook JR, Greiner TC, Hedvat C, Hill CE, Lim MS, Longtine JA, Sabath D, Wang YL. Laboratory practice guidelines for detecting and reporting JAK2 and MPL mutations in myeloproliferative neoplasms: a report of the association for molecular pathology. J Mol Diagn 2013; 15(6):733-44; PMID:23978506; http://dx.doi.org/10.1016/j.jmoldx.2013.07.002
  • Milosevic Feenstra JD, Nivarthi H, Gisslinger H, Leroy E, Rumi E, Chachoua I, Bagienski K, Kubesova B, Pietra D, Gisslinger B, et al. Whole exome sequencing identifies novel MPL and JAK2 mutations in triple negative myeloproliferative neoplasms. Blood 2016; 127(3):325-32; PMID:26423830; http://dx.doi.org/10.1182/blood-2015-07-661835
  • Cabagnols X, Favale F, Pasquier F, Messaoudi K, Defour JP, Ianotto JC, Marzac C, Le Couédiec JP, Droin N, Chachoua I, et al. Presence of atypical thrombopoietin receptor (MPL) mutations in triple negative essential thrombocythemia patients. Blood 2016; 127(3):333-42; PMID:26450985; http://dx.doi.org/10.1182/blood-2015-07-661983
  • Angona A, Fernández-Rodríguez C, Alvarez-Larrán A, Camacho L, Longarón R, Torres E, Pairet S, Besses C, Bellosillo B. Molecular characterisation of triple negative essential thrombocythaemia patients by platelet analysis and targeted sequencing. Blood Cancer J 2016; 6(8):e463; PMID:27564461; http://dx.doi.org/10.1038/bcj.2016.75
  • Kirschner MM, Schemionek M, Schubert C, Chatain N, Sontag S, Isfort S, Ortiz-Brüchle N, Schmitt K, Krüger K, Zerres K, et al. Dissecting genomic aberrations in myeloproliferative neoplasms by multiplex-PCR and next generation sequencing. PLoS One 2015; 10(4):e0123476; PMID:25894969; http://dx.doi.org/10.1371/journal.pone.0123476
  • Magor GW, Tallack MR, Klose NM, Taylor D, Korbie D, Mollee P, Trau M, Perkins AC. Rapid molecular profiling of myeloproliferative neoplasms using targeted exon resequencing of 86 genes involved in JAK-STAT signalling and epigenetic regulation. J Mol Diagn 2016; 18(5):707-18; PMID:27449473; http://dx.doi.org/10.1016/j.jmoldx.2016.05.006
  • Delic S, Rose D, Kern W, Nadarajah N, Haferlach C, Haferlach T, Meggendorfer M. Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera. Br J Haematol 2016; 175(3):419-26; PMID:27447873
  • Hussein K, Percy M, McMullin MF, Schwarz J, Schnittger S, Porret N, Martinez-Aviles L, Bellosillo-Paricio B, Giraudier S, Skoda R, et al. Clinical utility gene card for: hereditary thrombocythemia. Eur J Hum Genet 2014; 22(2):e1-e5; PMID:23736217; http://dx.doi.org/10.1038/ejhg.2013.117
  • Nelson ND, Marcogliese A, Bergstrom K, Scheurer M, Mahoney D, Bertuch AA. Thrombopoietin measurement as a key component in the evaluation of pediatric thrombocytosis. Pediatr Blood Cancer 2016; 63(8):1484-7; PMID:27100794; http://dx.doi.org/10.1002/pbc.26032
  • Randi ML, Geranio G, Bertozzi I, Micalizzi C, Ramenghi U, Tucci F, Notarangelo LD, Ladogana S, Menna G, Giordano P, et al. Are all cases of paediatric essential thrombocythaemia really myeloproliferative neoplasms? Br J Haematol 2015; 169(4):584-9; PMID:25716342; http://dx.doi.org/10.1111/bjh.13329
  • Swierczek S, Lima LT, Tashi T, Gregg XT, Prchal JT. Presence of polyclonal hematopoiesis in females with Ph-negative myeloproliferative neoplasms. Leukemia 2015; 29(12):2432-4; PMID:26369983
  • Hermouet S, Bigot-Corbel E, Gardie B. Pathogenesis of myeloproliferative neoplasms: role and mechanisms of chronic inflammation. Mediators Inflamm 2015; 2015:145293; PMID:26538820

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.